Filing Details
- Accession Number:
- 0000899243-20-032503
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-12-02 16:05:09
- Reporting Period:
- 2020-06-03
- Accepted Time:
- 2020-12-02 16:05:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1743881 | Bridgebio Pharma Inc. | BBIO | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1779990 | Thomas Michael Henderson | C/O Bridgebio Pharma, Inc. 421 Kipling Street Palo Alto CA 94301 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-06-03 | 784 | $30.04 | 261,399 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019.
- Represents the weighted average sale price of the shares sold from $30.00 to $30.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.